Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2025

Monday, November 14, 2016 1:10
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary:

The Type 2 Diabetes Market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2015 and 2025, almost doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. We anticipate that the type 2 diabetes market will experience a shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the glucagon-like peptide-1 receptor agonist (GLP-1RA) class and sodium-glucose co-transporter-2 inhibitor (SGLT-2I) class will occur; while dipeptidyl peptidase-4 inhibitors (DPP-4Is) will continue to grow, but at a much slower rate than previous years. GLP-1RAs and SGLT-2Is will experience the fastest growth of all classes at a CAGR of 12.2% and 13.0% respectively.

Get Sample Report@ https://www.wiseguyreports.com/sample-request/643856-pharmapoint-type-2-diabetes-global-drug-forecast-and-market-analysis-to-2025

Highlights

Key Questions Answered

- Although the T2D market has numerous well-established therapies, it is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the T2D market? 
- The late-stage T2D pipeline is heavily populated with me-too drugs from the classes of GLP-1RAs, DPP-4Is, and SGLT-2Is. Despite this, an oral GLP-1RA formulation and an osmotic pump which delivers subcutaneous exenatide for one year at a time are expected to be game changers in the GLP-1RA class. Both are in Phase III clinical trials and are expected to increase compliance among T2D patients. Will the late-stage drugs make a significant impact on the T2D market? Which of these drugs will have the highest peak sales at the highest CAGR, and why? 
- The diagnosed prevalence of T2D in the world skyrocketed in the past 10 years and will continue increasing at the fast pace. How will epidemiological changes impact the growth of the future market?

Get Exclusive Discount@ https://www.wiseguyreports.com/check-discount/643856-pharmapoint-type-2-diabetes-global-drug-forecast-and-market-analysis-to-2025

Key Findings

- The main driver of the enormous expansion of the T2D market will be the dramatic increase in disease prevalence, which is attributable to increased life expectancy and an increasingly sedentary and stressful lifestyle.
- The second largest driver will be the physicians’ efforts to delay disease progression through the use of combination therapies and novel branded drugs. 
- With the recent therapeutic guidelines putting emphasis on a patient-tailored approach in treating type 2 diabetes, pharmaceutical companies will achieve considerable success with their me-too drugs. 
- In the future, companies will have to shift their focus towards competitive pricing, “niche” drugs aimed at smaller patient groups, and drugs that increase patient compliance (through more convenient administration). 
- To date, no drug has demonstrated sustainable efficacy in the treatment of T2D. This unmet need presents a large opportunity for investment by drug developers.

Scope

- Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. 
- Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025. 
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market. 
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. 
- Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Leave an Enquiry@ https://www.wiseguyreports.com/enquiry/643856-pharmapoint-type-2-diabetes-global-drug-forecast-and-market-analysis-to-2025

Reasons to buy

The report will enable you to - 
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. 
- Develop business strategies by understanding the trends shaping and driving the global T2D therapeutics market. 
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T2D therapeutics market in future. 
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
- Track drug sales in the global T2D therapeutics market from 2015-2025. 
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Content:

1 Table of Contents 10 
    1.1 List of Tables 16 
    1.2 List of Figures 25 
2 Introduction 27 
    2.1 Catalyst 27 
    2.2 Related Reports 28 
3 Disease Overview 29 
    3.1 Etiology 30 
    3.2 Pathophysiology 31 
    3.3 Prognosis 33 
    3.4 Quality of Life 33 
    3.5 Symptoms 34 
4 Epidemiology 36 
    4.1 Disease Background 36 
    4.2 Risk Factors and Comorbidities 37 
    4.3 Global Trends 38 
      4.3.1 US 38 
      4.3.2 5EU 38 
      4.3.3 Japan 39 
      4.3.4 China and India 39 
    4.4 Forecast Methodology 40 
      4.4.1 Sources Used for Diagnosed Prevalence of T2D 45 
      4.4.2 Sources Not Used 56 
      4.4.3 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of T2D 57 
    4.5 Epidemiological Forecast for T2D (2015-2025) 68 
      4.5.1 Diagnosed Prevalent Cases of T2D 68 
      4.5.2 Age-Specific Diagnosed Prevalent Cases of T2D 70 
      4.5.3 Sex-Specific Diagnosed Prevalent Cases of T2D 72 
      4.5.4 Age-Standardized Diagnosed Prevalence of T2D 74 
      4.5.5 Prevalent Cases of Chronic Kidney Disease Among Diagnosed T2D Cases 76 
      4.5.6 Prevalent Cases of Cardiovascular Disease Among Diagnosed T2D Cases 76 
      4.5.7 Prevalent Cases of Overweight/Obesity Among Diagnosed T2D Cases 77 
      4.5.8 Prevalent Cases of Hypertension Among Diagnosed T2D Cases 78 
      4.5.9 Prevalent Cases of Dyslipidemia Among Diagnosed T2D Cases 79     Continued…..

   1.1 List of Tables 
Table 1: T2D Pathophysiology 32 
Table 2: Symptoms of T2D 35 
Table 3: Risk Factors and Comorbidities for T2D 37 
Table 4: 9MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of T2D 41 
Table 5: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of CKD Among Diagnosed Prevalent Cases of T2D 42 
Table 6: 8MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of CVD Among Diagnosed Prevalent Cases of T2D 42 
Table 7: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Overweight and Obesity Among Diagnosed Prevalent Cases of T2D 43 
Table 8: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Hypertension Among Diagnosed Prevalent Cases of T2D 44 
Table 9: 8MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Dyslipidemia Among Diagnosed Prevalent Cases of T2D 44 
Table 10: 9MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages ≥20 Years, N, 2015-2025 69 
Table 11: 9MM, Age-Specific Diagnosed Prevalent Cases of T2D, Both Sexes, N (Row %), 2015 71 
Table 12: 9MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, N (Row %), 2015 73 
Table 13: Diagnostic Tests and Typical Criteria for T2D 83    Continued…….

 1.2 List of Figures 
Figure 1: 9MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages ≥20 Years, N, 2015-2025 70 
Figure 2: 9MM, Age-Specific Diagnosed Prevalent Cases of T2D, Both Sexes, N, 2015 72 
Figure 3: 9MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, N, 2015 74 
Figure 4: 9MM, Age-Standardized Diagnosed Prevalence of T2D (%), Ages ≥20 Years, by Sex, 2015 75 
Figure 5: 9MM, Prevalent Cases of CKD Among Diagnosed T2D Cases, Both Sexes, Ages ≥20 Years, N, 2015 76 
Figure 6: 8MM, Prevalent Cases of CVD Among Diagnosed T2D Cases, Both Sexes, Ages ≥20 Years, N, 2015 77 
Figure 7: 9MM, Prevalent Cases of Overweight/Obesity Among Diagnosed T2D, Both Sexes, Ages ≥20 Years, N, 2015 78 
Figure 8: 9MM, Prevalent Cases of Hypertension Among Diagnosed T2D, Both Sexes, Ages ≥20Years, N, 2015 79 
Figure 9: 8MM, Prevalent Cases of Dyslipidemia Among Diagnosed T2D, Both Sexes, Ages ≥20 Years, N, 2015 80 
Figure 10: Incretin and SGLT-2I Mechanisms of Action 88 
Figure 11: ADA/EASD General Recommendations for Antihyperglycemic Therapy 89     Continued….

For more information or any query mail at sales@wiseguyreports.com

—-

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:
Norah Trent  

WISE GUY RESEARCH CONSULTANTS PVT LTD

75 Arlington Street, Suite 500,

Boston, Massaachusetts – 02116

United States of America                                                                                                                           

+1 646 845 9349 / +44 208 133 9349                                                       

https://www.wiseguyreports.com/

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.